Table 1.
Summary of associations between CYP2D6 genotype and breast cancer outcome. DFS: disease-free survival; EFS: event-free survival; HR: hazard ratio; PFS: progression-free survival; RFS: relapse-free survival; TTP: time to progression; wt: wild-type. *4, *5, *10, and *41 are non-functional CYP2D6 alleles.
| Study | # patients (treatment setting) | Took 2D6 inhibitors into account? | Comparison | HR | P value |
|---|---|---|---|---|---|
| Goetz (23) | 223 (adjuvant) | No | *4/*4 vs wt/*4 and wt/wt | DFS 1.86 | 0.089 |
| Goetz (31) | 190 (adjuvant) | Yes | Decreased vs Increased | RFS 1.74 | 0.034 |
| Lim (25) | 202 (metastatic) | No | *10/*10 vs others | TTP 5 mo vs 21.8 mo | 0.0032 |
| Nowell (26) | 162 (adjuvant) | No | wt/*4 and *4/*4 vs wt/wt | PFS 0.67 | 0.19 |
| Schroth (24) | 206 (adjuvant) | No | Nonfunctional allele carriers (*4, *5, *10, *41) vs wt | EFS 1.89 | 0.02 |
| Wegman (28) | 110 (adjuvant) | No | wt/*4 and *4/*4 vs wt/wt | RFS 0.33 | 0.14 |